Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
REPROS THERAPEUTICS INC. (RPRX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-17 | Jun-30-17 | Mar-31-17 | Dec-31-16 | Sep-30-16 | Jun-30-16 | Mar-31-16 | Dec-31-15 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Total revenues | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 2940.0% | -53.3% | -58.8% | -25.0% | 900.0% | 1400.0% | 1600.0% | 300.0% |
| Cost of goods sold | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.3 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | -2185.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 0.9 | 0.9 | 3.8 | 1.4 | 1.0 | 1.1 | 1.1 | 1.4 |
| General and administrative | 0.9 | 0.9 | 3.8 | 1.4 | 1.0 | 1.1 | 1.1 | 1.4 |
| Research and development | 1.0 | 1.1 | 2.1 | 2.6 | 3.2 | 3.2 | 3.8 | 4.8 |
| Other operating expenses | -0.3 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA [+] | -1.3 | -2.0 | -5.9 | -4.0 | -4.2 | -4.3 | -4.9 | -6.3 |
| EBITDA growth | -68.2% | -52.4% | 21.8% | -36.5% | -36.7% | -44.8% | -42.9% | -15.6% |
| EBITDA margin | -436.8% | -29214.3% | -84514.3% | -66400.0% | -41780.0% | -28626.7% | -28582.4% | -78450.0% |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -1.3 | -2.0 | -5.9 | -4.0 | -4.2 | -4.3 | -4.9 | -6.3 |
| EBIT growth | -68.2% | -52.4% | 21.7% | -36.5% | -36.7% | -44.9% | -43.0% | -15.7% |
| EBIT margin | -437.2% | -29228.6% | -84528.6% | -66416.7% | -41790.0% | -28633.3% | -28594.1% | -78487.5% |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.3 | -0.2 | | | | | | |
| Change in fair value of warrants | 0.3 | 0.2 | | | | | | |
| Pre-tax income | -1.6 | -2.2 | -5.9 | -4.0 | -4.2 | -4.3 | -4.8 | -6.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -1.6 | -2.2 | -5.9 | -4.0 | -4.2 | -4.3 | -4.8 | -6.3 |
| Net margin | -531.3% | -31414.3% | -84428.6% | -66316.7% | -41690.0% | -28533.3% | -28494.1% | -78387.5% |
| |
| Basic EPS [+] | ($0.04) | ($0.08) | ($0.22) | ($155.76) | ($0.17) | ($0.18) | ($0.20) | ($257.87) |
| Growth | -74.8% | -56.0% | 12.9% | -39.6% | -37.3% | -45.2% | -43.3% | 81040.4% |
| Diluted EPS [+] | $0.00 | $0.00 | $0.00 | ($0.16) | ($0.17) | $0.00 | ($0.20) | ($0.26) |
| Growth | -100.0% | -56.0% | -99.9% | -37.5% | -37.3% | -99.9% | -43.3% | -18.8% |
| |
| Shares outstanding (basic) [+] | 37.6 | 28.4 | 26.3 | 0.0 | 24.5 | 24.3 | 24.3 | 0.0 |
| Growth | 53.5% | 16.8% | 8.0% | 5.0% | 0.7% | 0.2% | 0.2% | -99.9% |
| Shares outstanding (diluted) [+] | 37,598.0 | 28,398.0 | 26,270.0 | 24.7 | 24.5 | 24,319.0 | 24.3 | 24.3 |
| Growth | 153392.5% | 16.8% | 107927.0% | 1.5% | 0.7% | 100068.9% | 0.2% | 3.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|